Gilead Sciences Inc. will use technology from AnaptysBio Inc. to develop new antibody drug leads.
Gilead (NASDAQ: GILD) made an upfront payment, according to AnaptysBio, a privately held company in San Diego, and will provide research funding to AnaptysBio.
Specific figures were not disclosed by AnaptysBio, and the company didn’t say which disease areas Foster City-based Gilead would target with the technology.
No comments:
Post a Comment